PRAX vs SGE.L
PRAX: Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing precision therapies for central nervous system disorders driven by neuronal imbalance. SGE.L: Sage provides cloud-native financial, HR, and payroll software solutions tailored to the needs of small and medium-sized enterprises globally.
Side-by-side fundamentals
| Metric | PRAX | SGE.L | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $368.03 | £10.86 | |
| Market cap as of 2026-08-24 | $10.3B | $13.3B | |
| PEG as of 2026-08-24 | -5.30 | n/a | |
| Net margin as of 2026-08-24 | -2137.5% | n/a | |
| Operating margin as of 2026-08-24 | -2340.3% | n/a | |
| ROE as of 2026-08-24 | -43.0% | n/a | |
| ROA as of 2026-08-24 | -40.2% | n/a | |
| Debt / equity as of 2026-08-24 | 0.00 | n/a | |
| Beta as of 2026-08-24 | 1.13 | n/a | |
| 1-year return as of 2026-08-24 close | +654.5% | -2.5% | PRAX higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.